Restorative Neurostimulation For Chronic Back Pain

Restorative Neurostimulation For Chronic Back Pain

With one in 10 Australians suffering from back pain – we’re excited to see new data from a local medical organisation making life-changing differences to those suffering.

An Australian-first trial of neurostimulation therapy led by Mainstay Medical has released their three-year clinical data – finding that their medical device improved back pain for 80 per cent of those involved. 

The device called ReActiv8 is a Restorative Neurostimulation system that is implanted in the back and generates pulses and stimulation to ease pain. 

It comes at a time that the country suffers from severely overstretched Emergency Departments – where back pain presentations sit within the top five ED admissions. 

Key Takeaways

  • 3-year real-world data collected at 5 sites across the UK.
  • 42 patients enrolled w/33 completing 3-year follow up.
  • No formal inclusion or exclusion criteria enforced outside the IFU and indications of the CE Mark.
  • 70% of patients reached the remitter threshold reporting mild to negligible pain (NRS ≤ 3) and 55% improved by more than 15 points on ODI.
  • 75% of patients had a substantial or profound improvement in NRS (>50%) and/or ODI (>20 point).
  • Patients reported a mean EQ-5D approaching an age matched UK population normal value.
  • No lead migrations.
  • Response to ReActiv8 consistent with the restorative mechanism of action and published pivotal trial data.

 3-Year ReActiv8-B Trial Data Summary

  • ReActiv8® provides an effective, durable, and safe treatment option for carefully selected patients with intractable CLBP and multifidus muscle dysfunction.
  • Trajectory and durability of clinical benefits are consistent with restoration of neuromuscular control and muscle rehabilitation. 
  • Restorative neurostimulation does not appear to be susceptible to loss of efficacy. (i.e., decreasing effectiveness over time)
  • The safety profile of the therapy remained favorable compared to available implantable neurostimulators for the treatment of other types of back pain.
  • An increasing proportion of participants are eliminating or decreasing opioidconsumption.


Skip to content